<DOC>
	<DOCNO>NCT00451204</DOCNO>
	<brief_summary>This double-blinded , placebo control study estriol pill versus placebo pill relapse remit multiple sclerosis . The study treatment add Copaxone injection subject . The primary outcome measure reduction relapse .</brief_summary>
	<brief_title>A Combination Trial Copaxone Plus Estriol Relapsing Remitting Multiple Sclerosis ( RRMS )</brief_title>
	<detailed_description>Multiple sclerosis ( MS ) relapse know significantly decreased pregnancy . This proposal establish whether oral treatment estriol , major estrogen pregnancy , induces decrease relapse relapse remit multiple sclerosis ( RRMS ) subject use combination injectable Copaxone . Previously , pilot study , demonstrate treatment RRMS subject oral estriol six month result significant reduction gadolinium enhance lesion serial brain MRIs ( Annals Neurology , 2002 ; 52:421-428 ) cause favorable shift immune response ( Journal Immunology , 2003 ; 171:6267-6274 ) . This add-on study aim extend previous finding treat longer focus clinical outcome . The combination Copaxone injection plus estriol pill ( 8 mg per day ) compare Copaxone injection plus placebo pill double blind trial . The duration treatment two year primary outcome measure relapse rate . Other outcome include disability measure brain MRI outcomes . Safety measure ( blood test gynecologic evaluation ) also follow correlation make serum estriol level efficacy safety . The overall goal study development new oral treatment , estriol , RRMS .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Glatiramer Acetate</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>Diagnosis relapse remit multiple sclerosis At least one relapse last two year Patients treat past total lymphoid irradiation , monoclonal antibody , T cell vaccination , cladribine , bone marrow transplantation , azathioprine , cyclophosphamide , methotrexate , mitoxantrone , cyclosporin Tysabri Clinically significant disease multiple sclerosis</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Multiple sclerosis</keyword>
	<keyword>estrogen</keyword>
	<keyword>estriol</keyword>
	<keyword>progesterone</keyword>
</DOC>